CLOCK may predict the response to fluvoxamine treatment in Japanese major depressive disorder patients

Taro Kishi, Tsuyoshi Kitajima, Masashi Ikeda, Yoshio Yamanouchi, Yoko Kinoshita, Kunihiro Kawashima, Tomo Okochi, Takenori Okumura, Tomoko Tsunoka, Norio Ozaki, Nakao Iwata

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Recent studies have shown that selective serotonin reuptake inhibitors (SSRIs) have circadian properties, suggesting that the antidepressive action of SSRIs may also be attributable to circadian mechanisms. Another study reported an association between clock gene (CLOCK) and improvements in insomnia symptoms from SSRIs treatment. Therefore, we examined the association between CLOCK and the efficacy of fluvoxamine treatment in 121 patients with Japanese major depressive disorder (MDD). The MDD patients in this study had scores of 12 or higher on the 17 items of the Structured Interview Guide for Hamilton Rating Scale for Depression (SIGH-D). We defined a therapeutic response as a decrease of more than a 50% in baseline SIGH-D within 8 weeks, and clinical remission as a SIGH-D score of less than seven at 8 weeks. We selected three tagging SNPs in CLOCK for the subsequent statistical association analysis. We detected a significant association between rs3736544, a synonymous polymorphism in exon 20, and the fluvoxamine therapeutic response in MDD in the allele/genotype-wise analyses. In addition, remission with fluvoxamine was also significantly associated with rs3736544. These associations remained significant after Bonferroni correction. Moreover, haplotype analysis findings supported these significant associations, which appeared to be due mainly to rs3736544, in the fluvoxamine therapeutic remission. Our results indicate that CLOCK genotype may be a predictor of fluvoxamine treatment response in Japanese MDD. However, our sample size was small, and a replication study using larger samples may be required for conclusive results.

Original languageEnglish
Pages (from-to)53-57
Number of pages5
JournalNeuroMolecular Medicine
Volume11
Issue number2
DOIs
Publication statusPublished - 01-06-2009

Fingerprint

Fluvoxamine
Major Depressive Disorder
Serotonin Uptake Inhibitors
Genotype
Therapeutics
Sleep Initiation and Maintenance Disorders
Sample Size
Haplotypes
Single Nucleotide Polymorphism
Exons
Alleles
Interviews
Depression
Genes

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Neurology
  • Cellular and Molecular Neuroscience

Cite this

Kishi, Taro ; Kitajima, Tsuyoshi ; Ikeda, Masashi ; Yamanouchi, Yoshio ; Kinoshita, Yoko ; Kawashima, Kunihiro ; Okochi, Tomo ; Okumura, Takenori ; Tsunoka, Tomoko ; Ozaki, Norio ; Iwata, Nakao. / CLOCK may predict the response to fluvoxamine treatment in Japanese major depressive disorder patients. In: NeuroMolecular Medicine. 2009 ; Vol. 11, No. 2. pp. 53-57.
@article{904791ab3db84dd8a608d386e54347ed,
title = "CLOCK may predict the response to fluvoxamine treatment in Japanese major depressive disorder patients",
abstract = "Recent studies have shown that selective serotonin reuptake inhibitors (SSRIs) have circadian properties, suggesting that the antidepressive action of SSRIs may also be attributable to circadian mechanisms. Another study reported an association between clock gene (CLOCK) and improvements in insomnia symptoms from SSRIs treatment. Therefore, we examined the association between CLOCK and the efficacy of fluvoxamine treatment in 121 patients with Japanese major depressive disorder (MDD). The MDD patients in this study had scores of 12 or higher on the 17 items of the Structured Interview Guide for Hamilton Rating Scale for Depression (SIGH-D). We defined a therapeutic response as a decrease of more than a 50{\%} in baseline SIGH-D within 8 weeks, and clinical remission as a SIGH-D score of less than seven at 8 weeks. We selected three tagging SNPs in CLOCK for the subsequent statistical association analysis. We detected a significant association between rs3736544, a synonymous polymorphism in exon 20, and the fluvoxamine therapeutic response in MDD in the allele/genotype-wise analyses. In addition, remission with fluvoxamine was also significantly associated with rs3736544. These associations remained significant after Bonferroni correction. Moreover, haplotype analysis findings supported these significant associations, which appeared to be due mainly to rs3736544, in the fluvoxamine therapeutic remission. Our results indicate that CLOCK genotype may be a predictor of fluvoxamine treatment response in Japanese MDD. However, our sample size was small, and a replication study using larger samples may be required for conclusive results.",
author = "Taro Kishi and Tsuyoshi Kitajima and Masashi Ikeda and Yoshio Yamanouchi and Yoko Kinoshita and Kunihiro Kawashima and Tomo Okochi and Takenori Okumura and Tomoko Tsunoka and Norio Ozaki and Nakao Iwata",
year = "2009",
month = "6",
day = "1",
doi = "10.1007/s12017-009-8060-7",
language = "English",
volume = "11",
pages = "53--57",
journal = "NeuroMolecular Medicine",
issn = "1535-1084",
publisher = "Humana Press",
number = "2",

}

Kishi, T, Kitajima, T, Ikeda, M, Yamanouchi, Y, Kinoshita, Y, Kawashima, K, Okochi, T, Okumura, T, Tsunoka, T, Ozaki, N & Iwata, N 2009, 'CLOCK may predict the response to fluvoxamine treatment in Japanese major depressive disorder patients', NeuroMolecular Medicine, vol. 11, no. 2, pp. 53-57. https://doi.org/10.1007/s12017-009-8060-7

CLOCK may predict the response to fluvoxamine treatment in Japanese major depressive disorder patients. / Kishi, Taro; Kitajima, Tsuyoshi; Ikeda, Masashi; Yamanouchi, Yoshio; Kinoshita, Yoko; Kawashima, Kunihiro; Okochi, Tomo; Okumura, Takenori; Tsunoka, Tomoko; Ozaki, Norio; Iwata, Nakao.

In: NeuroMolecular Medicine, Vol. 11, No. 2, 01.06.2009, p. 53-57.

Research output: Contribution to journalArticle

TY - JOUR

T1 - CLOCK may predict the response to fluvoxamine treatment in Japanese major depressive disorder patients

AU - Kishi, Taro

AU - Kitajima, Tsuyoshi

AU - Ikeda, Masashi

AU - Yamanouchi, Yoshio

AU - Kinoshita, Yoko

AU - Kawashima, Kunihiro

AU - Okochi, Tomo

AU - Okumura, Takenori

AU - Tsunoka, Tomoko

AU - Ozaki, Norio

AU - Iwata, Nakao

PY - 2009/6/1

Y1 - 2009/6/1

N2 - Recent studies have shown that selective serotonin reuptake inhibitors (SSRIs) have circadian properties, suggesting that the antidepressive action of SSRIs may also be attributable to circadian mechanisms. Another study reported an association between clock gene (CLOCK) and improvements in insomnia symptoms from SSRIs treatment. Therefore, we examined the association between CLOCK and the efficacy of fluvoxamine treatment in 121 patients with Japanese major depressive disorder (MDD). The MDD patients in this study had scores of 12 or higher on the 17 items of the Structured Interview Guide for Hamilton Rating Scale for Depression (SIGH-D). We defined a therapeutic response as a decrease of more than a 50% in baseline SIGH-D within 8 weeks, and clinical remission as a SIGH-D score of less than seven at 8 weeks. We selected three tagging SNPs in CLOCK for the subsequent statistical association analysis. We detected a significant association between rs3736544, a synonymous polymorphism in exon 20, and the fluvoxamine therapeutic response in MDD in the allele/genotype-wise analyses. In addition, remission with fluvoxamine was also significantly associated with rs3736544. These associations remained significant after Bonferroni correction. Moreover, haplotype analysis findings supported these significant associations, which appeared to be due mainly to rs3736544, in the fluvoxamine therapeutic remission. Our results indicate that CLOCK genotype may be a predictor of fluvoxamine treatment response in Japanese MDD. However, our sample size was small, and a replication study using larger samples may be required for conclusive results.

AB - Recent studies have shown that selective serotonin reuptake inhibitors (SSRIs) have circadian properties, suggesting that the antidepressive action of SSRIs may also be attributable to circadian mechanisms. Another study reported an association between clock gene (CLOCK) and improvements in insomnia symptoms from SSRIs treatment. Therefore, we examined the association between CLOCK and the efficacy of fluvoxamine treatment in 121 patients with Japanese major depressive disorder (MDD). The MDD patients in this study had scores of 12 or higher on the 17 items of the Structured Interview Guide for Hamilton Rating Scale for Depression (SIGH-D). We defined a therapeutic response as a decrease of more than a 50% in baseline SIGH-D within 8 weeks, and clinical remission as a SIGH-D score of less than seven at 8 weeks. We selected three tagging SNPs in CLOCK for the subsequent statistical association analysis. We detected a significant association between rs3736544, a synonymous polymorphism in exon 20, and the fluvoxamine therapeutic response in MDD in the allele/genotype-wise analyses. In addition, remission with fluvoxamine was also significantly associated with rs3736544. These associations remained significant after Bonferroni correction. Moreover, haplotype analysis findings supported these significant associations, which appeared to be due mainly to rs3736544, in the fluvoxamine therapeutic remission. Our results indicate that CLOCK genotype may be a predictor of fluvoxamine treatment response in Japanese MDD. However, our sample size was small, and a replication study using larger samples may be required for conclusive results.

UR - http://www.scopus.com/inward/record.url?scp=70349777037&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349777037&partnerID=8YFLogxK

U2 - 10.1007/s12017-009-8060-7

DO - 10.1007/s12017-009-8060-7

M3 - Article

VL - 11

SP - 53

EP - 57

JO - NeuroMolecular Medicine

JF - NeuroMolecular Medicine

SN - 1535-1084

IS - 2

ER -